2024
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, DOI: 10.1111/pcmr.13188.Peer-Reviewed Original ResearchSite of metastasisPattern of metastatic diseaseMelanoma mortalityRetrospective observational cohort studyCause of cancer mortalityDistant lymph nodesObservational cohort studyDiagnosis to deathImmunotherapy eraAdvanced melanomaMetastatic diagnosisMetastatic diseaseMetastatic melanomaImmunotherapy treatmentRespiratory failureCause of deathMedian timeLymph nodesTherapeutic advancesCohort studyMelanomaImmunotherapyMechanism of deathPatientsEnd of life
2023
627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Rodon J, Chaney M, Cohen J, Garyantes T, Lin J, Ishizuka J, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. 2023, a716-a716. DOI: 10.1136/jitc-2023-sitc2023.0627.Peer-Reviewed Original Research1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Rodon J, Chaney M, Cohen J, Garyantes T, Ishizuka J, Lin J, Lorusso P, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. Annals Of Oncology 2023, 34: s663. DOI: 10.1016/j.annonc.2023.09.2235.Peer-Reviewed Original Research
2021
Going viral: HBV-specific CD8+ tissue-resident memory T cells propagate anti-tumor immunity
Wei J, Ishizuka JJ. Going viral: HBV-specific CD8+ tissue-resident memory T cells propagate anti-tumor immunity. Immunity 2021, 54: 1630-1632. PMID: 34380061, DOI: 10.1016/j.immuni.2021.07.014.Commentaries, Editorials and Letters